Clearside Biomedical (Clearside Biomedical) Effective Interest Rate on Debt % : 984.84% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Clearside Biomedical Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Clearside Biomedical's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $9.61 Mil. Clearside Biomedical's average total debt for the quarter that ended in Mar. 2024 was $0.98 Mil. Therefore, Clearside Biomedical's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 984.84%.

Clearside Biomedical Effective Interest Rate on Debt % Historical Data

The historical data trend for Clearside Biomedical's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearside Biomedical Effective Interest Rate on Debt % Chart

Clearside Biomedical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

340.71

814.62

Clearside Biomedical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															691.23	771.74	936.01	867.84	984.84

Competitive Comparison of Clearside Biomedical's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Clearside Biomedical's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clearside Biomedical's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Clearside Biomedical's Effective Interest Rate on Debt % falls into.

Clearside Biomedical Effective Interest Rate on Debt % Calculation

Clearside Biomedical's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2022 )	+	Total Debt (A: Dec. 2023 ))	/ count )
=	-1 * -9.36	/	( (1.285	+	1.013)	/ 2 )
=	-1 * -9.36	/	1.149
=	814.62 %

where

	Total Debt (A: Dec. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.936	+	0.349
=	1.285

	Total Debt (A: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.649	+	0.364
=	1.013

Clearside Biomedical's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Dec. 2023 )	+	Total Debt (Q: Mar. 2024 ))	/ count )
=	-1 * -9.612	/	( (1.013	+	0.939)	/ 2 )
=	-1 * -9.612	/	0.976
=	984.84 %

where

	Total Debt (Q: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.649	+	0.364
=	1.013

	Total Debt (Q: Mar. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0.572	+	0.367
=	0.939

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Clearside Biomedical (NAS:CLSD) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Clearside Biomedical Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Clearside Biomedical's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clearside Biomedical (Clearside Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearside Biomedical Inc (NAS:CLSD) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

CLM:Germany CLM:Germany

Address

900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005

Website

https://www.clearsidebio.com

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Executives

Charles A. Deignan	officer: Chief Financial Officer	C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
George M Lasezkay	director	1301 SECOND AVE., SUITE 4200, SEATTLE WA 98101
Bradford T Whitmore	10 percent owner	5215 OLD ORCHARD ROAD, SUITE 620, SKOKIE IL 60077
Nancy J Hutson	director	64 MONTAUK AVENUE, STONINGTON CT 06378
Clay Thorp	director, 10 percent owner	C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Thomas Ciulla	officer: Chief Medical Officer	C/O CLEARSIDE BIOMEDICAL, INC., 900 NORTH POINT PARKWAY, SUITE 200, ALPHARETTA GA 30005
Benjamin R Yerxa	director	INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
William D. Humphries	director	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Jeffrey L Edwards	director	2525 DUPONT DR, IRVINE CA 92612
Daniel H. White	director, officer: President and CEO	C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
Gerald D. Cagle	director	135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921
Brion S. Raymond	officer: Chief Commercial Officer	C/O CLEARSIDE BIOMEDICAL, INC., 1220 OLD ALPHARETTA ROAD, SUITE 300, ALPHARETTA GA 30005
Christy L Shaffer	director	INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
Hatteras Venture Advisors Iv Sbic, Llc	10 percent owner	280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701
Hatteras Venture Advisors Iii, Llc	10 percent owner	280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701